Peri-implantitisPhase 2/3NCT02575274
Peri-Implantitis Surgical Treatment an RCT Study
A Phase 2/3 study testing Surgical flaps in people with Peri-implantitis, run by Mr. Sergio Diniz Ferreira at 1 site in Brazil.
Trial summary
The purpose of this experimental study in humans is to evaluate and compare, the regenerative therapy for the treatment of peri-implantitis using different bone substitutes and absorbable membranes with surgical therapy without the use of materials for regeneration. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Peri-implantitis
- What is being tested?
- Surgical flaps
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteBrazil
- Study dates
- Sep 2013to Jul 2016
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- It will include individuals diagnosed with early to moderate peri-implantitis (probing depth between 5 and 10 mm) rehabilitated with implant supporting fixed prosthesis for at least 6 months. Due to the great variation in implants' length the probing depth can shows great variability. In this way it is complicated to establish a cutoff point to define the severity of the disease. So in order to minimize this limitation, the peri-implant bone defect should be angular or circular involving at least 3 threads and should not exceed 50% of the total length of the implant.
Who cannot join
- Smokers
- Individuals with blood glucose more than 120 mg/dl or Insulin dependent diabetes
- Individuals who have undergone treatment of peri-implant disease over the last 6 months
- Individuals who used antibiotic therapy, for any reason, in the last 3 months
- Individuals who have any systemic condition that prevents surgical treatment
- Refusal to sign the informed consent
Show all 9Show fewer
- A history of local radiotherapy to the head and neck region
- Pregnancy and lactation
- Active, uncontrolled periodontal pathology of the remaining dentition
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Federal University of Minas Gerais
Belo Horizonte, Minas Gerais, 30110031
About this study
Official title: Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial
The purpose of this experimental study in humans is to evaluate and compare, the regenerative therapy for the treatment of peri-implantitis using different bone substitutes and absorbable membranes with surgical therapy without the use of materials for regeneration.
Read the detailed description
Specifics aims
- Compare radiographic and clinical results of guided bone regeneration (GBR) technique in the treatment of peri-implantitis using membrane and bone substitute (JHS HAP91 ® + JHS COL-HAP-91®) to surgical approach without bone substitutes.
- Compare the radiographic and clinical results of GBR with surgical therapy without biomaterials
- Evaluate radiographic changes in bone levels after GBR therapy.
- Evaluate changes in probing depth (PD) after GBR therapy.
- Evaluate the long term predictability of GBR and surgical therapy in the treatment of peri-implantitis.
Study Design This prospective clinical trial will recruit to clinical periodontal and peri-implant examination, individuals diagnosed with peri-implantitis who fit the eligibility criteria described below. After the clinical examination the individuals will receive oral hygiene instructions and those diagnosed with peri-implantitis will take implants standardized radiographic exams prior to surgery. Only circular and/or bowl-shaped bone defects will be selected for the study.
Sampling In this design the inclusion of at least 15 individuals is estimated for each experimental group when it performs a sample calculation with power of 90% and a significance level of 95% considering an outcome data from previous studies.
Individuals diagnosed with peri-implantitis will be recruited in two specialized private treatment centers and post graduation schools from June 2013 to June 2016. The total sample of 15 eligible implants with peri-implantitis per group will be treated (n total = 30).
Randomization process After the clinical and radiographic examination individuals will be scheduled for completion of the surgical procedure. It will be carried out a process of "Central Stratified Randomization" which shall consist of forty five opaque envelopes, where it will be placed the IDs of each treatment group (group 1 or group 2). The envelopes shall be sealed and shuffled. Each new implant in the study, at the time of surgery, after the cleaning and decontamination of the surface will be sorted for one treatment group. One envelope of subsequent numbering will be opened by a surgical assistant to determine the procedure that will be performed. In this way the individuals will be listed in each of the two different treatment groups.
Peri-implantitis treatment Individuals will be allocated at the time of surgery in each of the following treatment groups: Group 1: surgical debridement of the defect and mechanical decontamination by means of plastic curettes, bone defects will be treated later with JHS COL-HAP91® + JHS HAP-91® (n = 15); Group 2: only surgical debridement and mechanical decontamination by means of plastic curettes (n = 15). All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
All individuals should follow the following post operative drug protocol: use of Amoxicillin 500 mg 3 times a day for 07 days after surgery. Individuals allergic to Amoxicillin will be treated with Clindamycin 300 mg, 3 times a day, for 07 days. Analgesics, Tylenol 750 mg 3 times a day, and anti-inflammatory Nimesulide 100 mg 2 times a day will be prescribed.
Oral hygiene care will be strengthened and will be prescribed mouthwash two times a day (12/12 hour) 0.12% chlorhexidine during 21 days. Postoperative control will be carried out with 5, 10, 15 and 30 days. Return and maintenance shall be carried out with 60 and 90 days, at these moments new clinical examination will be held to evaluate peri-implant conditions, reinforcement for oral hygiene and prophylaxis. Recall visits with 6, 12 and 18 months will be made to measure peri-implant and maintenance parameters.
Standardized radiographic examinations will be carried out previously to the surgery, immediately after the surgery and with 6, 12 and 18 months for assessment of changes in bone levels obtained with the surgical procedures. Through comparison and measures carried out with x-rays performed preoperatively benchmarks as tops and valleys of the threads and the head of the implants will be used to carry out the measurements.
The x-rays will default on the exposure time and the positioning of the radiographic taking. Positioners and records will be used with dense silicone bite for standardization of survey position.
Peri-implant mucositis diagnosis An implant will be diagnosed with peri-implant mucositis in the presence peri-implant bleeding probing without bone loss.
Peri-implantitis diagnosis An implant will be diagnosed with peri-implantitis when present bleeding on probing and/or suppuration, a probing depth (PDi) greater than or equal to 5 mm and presence of bone loss confirmed by radiography, or a value of PDi greater than or equal to 5 mm even in the absence of bleeding or suppuration but presence of bone loss after radiographic examination.
The implants that shows PDi greater than or equal to 5 mm with bleeding on probing and not present bone loss, confirmed by radiographic examination, will be diagnosed as peri-implant mucositis and will not be included in the study.
Determination of peri-implant clinical status The following clinical parameters will be evaluated and recorded for all implants present in the oral cavity, with the exception of bone loss that will meet specific criteria (only implants with clinical signs of peri-implantitis): Plaque Index (PIi) (Silness and Löe, 1964 modified by Mombelli et al. 1987) (26, 27); Peri-implant probing depth in millimeters (PPDi); % os sites with peri-implant bleeding on probing (BOPi); Peri-implant suppuration (absence or presence) (Si); The presence and amount of peri-implant keratinized mucosa (KMi) (28); Presence of peri-implant bone loss in radiographic examination (BL).
Determination of radiographic bone level peri-implant Evaluation of peri-implant bone level will be held through periapical x-rays taken at the time of the examination of individuals by parallelism or standardized cone along with use of radiographic film positioners and acrylic bite records for standardization of position of the radiographic taking. Immediately after the surgical treatment, will be carried out x-rays and after 6, 12 and 18 months.
Evaluation of postoperative radiographic measurements must be carried out by another examiner, which does not have knowledge of the surgical treatment that was performed. Measures will be undertaken to assessment of post-treatment bone changes. For this it will be used as reference points the base of the platform and the turns of the implant.
Data of interest Through the assessment of individuals' records, shall be noted the following data concerning implants: implant installation time in months; amount of installed implants; implant function time in months; reason for tooth loss; periodontal phenotype (thin or thick); evaluation of occlusal functionality, type of the implants, implant surface treatment (present/absent) and when available type of surface treatment.
Clinical periodontal status The following clinical parameters will be evaluated and recorded for all teeth present in the oral cavity: Plaque Index (PIi) (Silness and Löe, 1964)(27); Pocket probing depth (PPD); Clinical attachment level (CAL); % of sites with periodontal bleeding on probing (BOP).
- Conditions
- Peri-implantitis
- Being tested
- Surgical flaps
- Keywords
- Peri-implantitis, Peri-implant disease, Dental implants, Guided bone regeneration
- Medical subject headings
- Peri-Implantitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical flapsProcedure or surgery
Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
| Study group | Role | What they receive |
|---|---|---|
| JHS COL-HAP91 + JHS HAP-91 | Experimental | Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed. Receives: Procedure: Surgical flaps |
| surgical and mechanical debridement | Other | Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed. Receives: Procedure: Surgical flaps |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in peri-implant probing depth
Peri-implant probing depth measured in millimeters with peri-implant probe
Measured: one year and half. Pre-operative, after surgery: 6, 12 and 18 months
Secondary outcomes (1)
Changes in radiographic marginal bone level on standardized intraoral radiographs
Evaluation of peri-implant bone level will be held through periapical x-rays taken at the time of the examination of individuals by parallelism or standardized cone along with use of radiographic film positioners and acrylic bite records for standardization of position of the radiographic taking.
Measured: One year and half. Pre operative and after surgery: immediatelly, 6, 12 and 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2015 (estimated)
- Study startSep 2013
- Primary completionDec 2015 (estimated)
- Study completionJul 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peri-implantitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mr. Sergio Diniz Ferreira
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Mr. Sergio Diniz Ferreira, Federal University of Minas Gerais
- Investigators
- Sergio D Ferreira, MsC, Principal investigator, Doctoral student
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02575274
- Sponsor's protocol ID
- RCT peri-implantitis
- Status last verified
- Oct 2015
- First submitted
- 29 Jan 2015
- Last updated
- 14 Oct 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT02575274
- Acronym / sponsor ID
- RCT peri-implantitis
- Conditions
- Peri-implantitis
- Keywords
- Peri-implantitis, Peri-implant disease, Dental implants, Guided bone regeneration
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Mr. Sergio Diniz FerreiraUniversity, hospital or other
- Study start
- Sep 2013
- Primary completion
- Dec 2015 (estimated)
- Study completion
- Jul 2016 (estimated)
- First posted
- 14 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this experimental study in humans is to evaluate and compare, the regenerative therapy for the treatment of peri-implantitis using different bone substitutes and absorbable membranes with surgical therapy without the use of materials for regeneration.
Detailed description
Specifics aims
- Compare radiographic and clinical results of guided bone regeneration (GBR) technique in the treatment of peri-implantitis using membrane and bone substitute (JHS HAP91 ® + JHS COL-HAP-91®) to surgical approach without bone substitutes.
- Compare the radiographic and clinical results of GBR with surgical therapy without biomaterials
- Evaluate radiographic changes in bone levels after GBR therapy.
- Evaluate changes in probing depth (PD) after GBR therapy.
- Evaluate the long term predictability of GBR and surgical therapy in the treatment of peri-implantitis.
Study Design This prospective clinical trial will recruit to clinical periodontal and peri-implant examination, individuals diagnosed with peri-implantitis who fit the eligibility criteria described below. After the clinical examination the individuals will receive oral hygiene instructions and those diagnosed with peri-implantitis will take implants standardized radiographic exams prior to surgery. Only circular and/or bowl-shaped bone defects will be selected for the study.
Sampling In this design the inclusion of at least 15 individuals is estimated for each experimental group when it performs a sample calculation with power of 90% and a significance level of 95% considering an outcome data from previous studies.
Individuals diagnosed with peri-implantitis will be recruited in two specialized private treatment centers and post graduation schools from June 2013 to June 2016. The total sample of 15 eligible implants with peri-implantitis per group will be treated (n total = 30).
Randomization process After the clinical and radiographic examination individuals will be scheduled for completion of the surgical procedure. It will be carried out a process of "Central Stratified Randomization" which shall consist of forty five opaque envelopes, where it will be placed the IDs of each treatment group (group 1 or group 2). The envelopes shall be sealed and shuffled. Each new implant in the study, at the time of surgery, after the cleaning and decontamination of the surface will be sorted for one treatment group. One envelope of subsequent numbering will be opened by a surgical assistant to determine the procedure that will be performed. In this way the individuals will be listed in each of the two different treatment groups.
Peri-implantitis treatment Individuals will be allocated at the time of surgery in each of the following treatment groups: Group 1: surgical debridement of the defect and mechanical decontamination by means of plastic curettes, bone defects will be treated later with JHS COL-HAP91® + JHS HAP-91® (n = 15); Group 2: only surgical debridement and mechanical decontamination by means of plastic curettes (n = 15). All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
All individuals should follow the following post operative drug protocol: use of Amoxicillin 500 mg 3 times a day for 07 days after surgery. Individuals allergic to Amoxicillin will be treated with Clindamycin 300 mg, 3 times a day, for 07 days. Analgesics, Tylenol 750 mg 3 times a day, and anti-inflammatory Nimesulide 100 mg 2 times a day will be prescribed.
Oral hygiene care will be strengthened and will be prescribed mouthwash two times a day (12/12 hour) 0.12% chlorhexidine during 21 days. Postoperative control will be carried out with 5, 10, 15 and 30 days. Return and maintenance shall be carried out with 60 and 90 days, at these moments new clinical examination will be held to evaluate peri-implant conditions, reinforcement for oral hygiene and prophylaxis. Recall visits with 6, 12 and 18 months will be made to measure peri-implant and maintenance parameters.
Standardized radiographic examinations will be carried out previously to the surgery, immediately after the surgery and with 6, 12 and 18 months for assessment of changes in bone levels obtained with the surgical procedures. Through comparison and measures carried out with x-rays performed preoperatively benchmarks as tops and valleys of the threads and the head of the implants will be used to carry out the measurements.
The x-rays will default on the exposure time and the positioning of the radiographic taking. Positioners and records will be used with dense silicone bite for standardization of survey position.
Peri-implant mucositis diagnosis An implant will be diagnosed with peri-implant mucositis in the presence peri-implant bleeding probing without bone loss.
Peri-implantitis diagnosis An implant will be diagnosed with peri-implantitis when present bleeding on probing and/or suppuration, a probing depth (PDi) greater than or equal to 5 mm and presence of bone loss confirmed by radiography, or a value of PDi greater than or equal to 5 mm even in the absence of bleeding or suppuration but presence of bone loss after radiographic examination.
The implants that shows PDi greater than or equal to 5 mm with bleeding on probing and not present bone loss, confirmed by radiographic examination, will be diagnosed as peri-implant mucositis and will not be included in the study.
Determination of peri-implant clinical status The following clinical parameters will be evaluated and recorded for all implants present in the oral cavity, with the exception of bone loss that will meet specific criteria (only implants with clinical signs of peri-implantitis): Plaque Index (PIi) (Silness and Löe, 1964 modified by Mombelli et al. 1987) (26, 27); Peri-implant probing depth in millimeters (PPDi); % os sites with peri-implant bleeding on probing (BOPi); Peri-implant suppuration (absence or presence) (Si); The presence and amount of peri-implant keratinized mucosa (KMi) (28); Presence of peri-implant bone loss in radiographic examination (BL).
Determination of radiographic bone level peri-implant Evaluation of peri-implant bone level will be held through periapical x-rays taken at the time of the examination of individuals by parallelism or standardized cone along with use of radiographic film positioners and acrylic bite records for standardization of position of the radiographic taking. Immediately after the surgical treatment, will be carried out x-rays and after 6, 12 and 18 months.
Evaluation of postoperative radiographic measurements must be carried out by another examiner, which does not have knowledge of the surgical treatment that was performed. Measures will be undertaken to assessment of post-treatment bone changes. For this it will be used as reference points the base of the platform and the turns of the implant.
Data of interest Through the assessment of individuals' records, shall be noted the following data concerning implants: implant installation time in months; amount of installed implants; implant function time in months; reason for tooth loss; periodontal phenotype (thin or thick); evaluation of occlusal functionality, type of the implants, implant surface treatment (present/absent) and when available type of surface treatment.
Clinical periodontal status The following clinical parameters will be evaluated and recorded for all teeth present in the oral cavity: Plaque Index (PIi) (Silness and Löe, 1964)(27); Pocket probing depth (PPD); Clinical attachment level (CAL); % of sites with periodontal bleeding on probing (BOP).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JHS COL-HAP91 + JHS HAP-91 | Experimental | Procedure: Surgical flapsSurgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed. |
| surgical and mechanical debridement | Other | Procedure: Surgical flapsSurgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- It will include individuals diagnosed with early to moderate peri-implantitis (probing depth between 5 and 10 mm) rehabilitated with implant supporting fixed prosthesis for at least 6 months. Due to the great variation in implants' length the probing depth can shows great variability. In this way it is complicated to establish a cutoff point to define the severity of the disease. So in order to minimize this limitation, the peri-implant bone defect should be angular or circular involving at least 3 threads and should not exceed 50% of the total length of the implant.
Key exclusion criteria (9 listed)
- Smokers
- Individuals with blood glucose more than 120 mg/dl or Insulin dependent diabetes
- Individuals who have undergone treatment of peri-implant disease over the last 6 months
- Individuals who used antibiotic therapy, for any reason, in the last 3 months
- Individuals who have any systemic condition that prevents surgical treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical flapsSurgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%. | Procedure or surgery | JHS COL-HAP91 + JHS HAP-91, surgical and mechanical debridement |
Primary outcome
Changes in peri-implant probing depth
Time frame: one year and half. Pre-operative, after surgery: 6, 12 and 18 months
Peri-implant probing depth measured in millimeters with peri-implant probe
1 secondary outcome
Changes in radiographic marginal bone level on standardized intraoral radiographs
Time frame: One year and half. Pre operative and after surgery: immediatelly, 6, 12 and 18 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2015.
Related trials for Peri-implantitis
Not yet recruiting
Effect of Customized Versus Stock Healing Abutments on Peri-Implant Soft Tissue
Peri-Implantitis
RecruitingObservational study
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
Peri Implantitis, Peri Implant Mucositis
Not yet recruitingObservational study
Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs
Peri-implantitis, Alveolar Bone Loss
RecruitingObservational study
Access to Probing and Peri-implant Diseases
Peri-implantitis, Peri-implant Bone Loss
Not yet recruitingObservational study
ATR-FTIR and Raman Spectroscopy of Peri-Implant Crevicular Fluid in Peri-Implantitis
Peri-Implantitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sergio D Ferreira, MsC principal investigator
Doctoral student
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Surgical flaps in people with Peri-implantitis, run by Mr. Sergio Diniz Ferreira at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in peri-implant probing depth (time frame: one year and half. Pre-operative, after surgery: 6, 12 and 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2015.